Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.48 |
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29407853 | 1.00 | MDM4 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL178741 | 1.00 | MDM4 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL119481 | 1.00 | MDM4 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL30055069 | 1.00 | MDM4 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL25358998 | 0.94 | MDM2 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL31398353 | 0.94 | MDM2 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL31398346 | 0.94 | MDM2 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL31689003 | 0.93 | MDM2 (0.50) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL29398655 | 0.92 | TLR2 (0.48) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL14417867 | 0.91 | CASP3 (0.46) | MDM4TP53TLR2CASP3MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118403181-A | Novel multifunctional nano-drug carrier material and preparation method and application thereof | 浙江工业大学 | 2024-07-30 | — | — | CN | claimed |
| CN-118324868-A | Process for the preparation of desmopressin EP impurities E and F | 梯尔希（南京）药物研发有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-115043901-B | Dopaminization modified glutamine polypeptide, antibody thereof and application thereof | 济宁医学院附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-115043901-A | Dopamine modified glutamine polypeptide and antibody and application thereof | 济宁医学院附属医院 | 2022-09-13 | — | — | CN | claimed |
| CN-113150075-B | Cyclic poly-arginine cell-penetrating peptide molecule and synthesis method and application thereof | 合肥工业大学 | 2022-07-26 | — | — | CN | claimed |
| EP-4741423-A2 | ANTIBODY-DRUG CONJUGATES AND THEIR USES | Mablink Bioscience (FR) | 2026-05-13 | — | — | EP | disclosed |
| CN-122011117-A | Cyclic peptide for resisting ultraviolet injury and application thereof in cosmetics | 深圳肽盛渼生物科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4729529-A1 | PREPARATION OF PEPTIDE INHIBITOR OF INTERLEUKIN-23 RECEPTOR AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| US-12569536-B2 | Macrocyclic peptides for targeted inhibition of autophagy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4702986-A1 | POLYPEPTIDE AND USE THEREOF | Biocells (Beijing) Biotech Co., Ltd. (CN) | 2026-03-04 | — | — | EP | disclosed |
| EP-4225772-B1 | CYCLIC APELIN RECEPTOR AGONISTS | NXERA PHARMA UK LTD (GB) | 2026-02-25 | — | — | EP | disclosed |
| US-12551535-B2 | Peptide pharmaceuticals for insulin resistance | MEDERIS DIABETES, LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | FUJIFILM CORPORATION (JP) | 2022-05-03 | — | — | US | disclosed |
| US-20220119445-A1 | SYNTHETIC CYCLIC PEPTIDES AND METHODS OF PREPARATION AND USE THEREOF | NATIONAL SCIENCE FOUNDATION | 2022-04-21 | — | — | US | disclosed |
| US-20220096594-A1 | MACROCYCLIC PEPTIDES FOR TARGETED INHIBITION OF AUTOPHAGY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-03-31 | — | — | US | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | PALATIN TECHNOLOGIES, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20220088146-A1 | Melanocortin Receptor-Specific Peptide Formulations and Methods for Gastrointestinal Tract-Specific Delivery | PALATIN TECHNOLOGIES INC (US) | 2022-03-24 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-20220041656-A1 | NOVEL COMPOUND AND ANGIOGENIC AGENT COMPRISING SAME | HIPEP LABORATORIES (JP) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041656-A1 | NOVEL COMPOUND AND ANGIOGENIC AGENT COMPRISING SAME | VEGFA, FLT1, FLT4 | MDM4 4766/4885TP53 3939/4885TLR2 1629/4885 |
| US-12569536-B2 | Macrocyclic peptides for targeted inhibition of autophagy | ATG7, SQSTM1, VIP | MDM4 3017/4885TP53 415/4885TLR2 1741/4885 |
| US-12551535-B2 | Peptide pharmaceuticals for insulin resistance | IAPP, GLP1R, INSR | MDM4 2645/4885TP53 3467/4885TLR2 550/4885 |
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | MC3R, MC1R, MC2R | MDM4 4380/4885TP53 3497/4885TLR2 502/4885 |
| US-20220088146-A1 | Melanocortin Receptor-Specific Peptide Formulations and Methods for Gastrointestinal Tract-Specific Delivery | MC3R, GIPR, MC1R | MDM4 4773/4885TP53 3820/4885TLR2 905/4885 |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | VIP, NPPA, NGLY1 | MDM4 4154/4885TP53 1409/4885TLR2 3116/4885 |
| US-20220119445-A1 | SYNTHETIC CYCLIC PEPTIDES AND METHODS OF PREPARATION AND USE THEREOF | VIP, PTMS, IAPP | MDM4 1657/4885TP53 1578/4885TLR2 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.